脊髄損傷（SCI）は、脊髄に生じた損傷または外傷と定義されています。SCI は、機能の喪失または障害を引き起こし、可動性または感覚の低下をもたらす可能性があります。それは通常、外傷、横断性脊髄炎、ポリオ、二分脊椎またはフリードライヒ運動失調症によって引き起こされます。脊髄損傷の徴候と症状には、首、頭または背中の極度の背中の痛みまたは圧力、体のあらゆる部分の麻痺、手、指、足またはつま先のしびれ、うずきまたは感覚の喪失、膀胱や腸の制御不能、歩行困難、呼吸障害などが含まれます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spinal Cord Injury - Overview
Spinal Cord Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinal Cord Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinal Cord Injury - Companies Involved in Therapeutics Development
Spinal Cord Injury - Drug Profiles
Spinal Cord Injury - Dormant Projects
Spinal Cord Injury - Discontinued Products
Spinal Cord Injury - Product Development Milestones
Featured News & Press Releases
Sep 17, 2022: NervGen Pharma presenting at upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting
May 20, 2022: Birmingham research brings hope for spinal cord injury treatment
May 18, 2022: NervGen hosting ppanel discussion with leading experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
May 12, 2022: NervGen Pharma receives approval to proceed to the final dose cohort in phase 1 clinical trial of NVG-291
Mar 31, 2022: NervGen presenting interim phase 1 clinical trial data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Mar 23, 2022: NervGen Pharma to present at 2022 virtual growth conference presented by Maxim Group
Mar 15, 2022: NervGen Pharma receives approval from Safety Review Committee to proceed to second cohort in multiple ascending dose portion of phase 1 clinical trial of NVG-291
Jan 10, 2022: NervGen Pharma announces intent to conduct groundbreaking spinal cord injury clinical trial in exclusive partnership with Shirley Ryan AbilityLab, 1-Ranked Hospital in Physical Medicine & Rehabilitation
Dec 22, 2021: NervGen Pharma receives ethics board approval for multiple ascending dose portion of NVG-291 phase 1 trial
Nov 04, 2021: NervGen presents additional phase 1 clinical trial data for NVG-291 at Neuroscience 2021 / safety review committee provides recommendation to proceed to multiple ascending dose portion of the trial
Oct 27, 2021: NervGen Pharma announces spinal cord injury clinical advisory board
Oct 18, 2021: NervGen presents interim phase 1 clinical trial data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 demonstrated to be well tolerated along with a favorable pharmacokinetic profile
Sep 27, 2021: NervGen Pharma partners with Imeka to use novel neuroimaging technology in clinical trials
Sep 12, 2021: NervGen Pharma presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 08, 2021: Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Spinal Cord Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Spinal Cord Injury - Dormant Projects, 2022
Spinal Cord Injury - Dormant Projects, 2022 (Contd..1)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..2)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..3)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..4)
Spinal Cord Injury - Discontinued Products, 2022
List of Figures
Number of Products under Development for Spinal Cord Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
